Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.49 |
| ▸ | BCR | P11274 | 6/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23489403 | 0.86 | ITGB1 (0.41) | ABL1BCRROCK1MAPTL3MBTL1 | |
| SCHEMBL23455498 | 0.86 | ITGB1 (0.54) | ABL1BCRROCK1MAPTSMN1; SMN2 | |
| SCHEMBL30000520 | 0.86 | ITGB1 (0.54) | ABL1BCRROCK1MAPTSMN1; SMN2 | |
| SCHEMBL23455496 | 0.86 | ITGB1 (0.54) | ABL1BCRROCK1MAPTSMN1; SMN2 | |
| SCHEMBL23455434 | 0.86 | ITGB1 (0.46) | ABL1BCRROCK1MAPTL3MBTL1 | |
| SCHEMBL23455435 | 0.86 | ITGB1 (0.46) | ABL1BCRROCK1MAPTL3MBTL1 | |
| SCHEMBL23518428 | 0.82 | ITGB1 (0.39) | ABL1BCRROCK1MAPTL3MBTL1 | |
| SCHEMBL23518501 | 0.80 | MAPT (0.46) | ABL1BCRROCK1MAPTL3MBTL1 | |
| SCHEMBL23455528 | 0.76 | MAPT (0.67) | ABL1BCRROCK1MAPTTP53 | |
| SCHEMBL23518304 | 0.75 | LMNA (0.45) | MAPTL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | ABL1 3190/4885BCR 4495/4885ROCK1 599/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ABL1 3190/4885BCR 4495/4885ROCK1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.